Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG

immunoglobulin isotypes

- 1 Alfredo Ramírez-Reveco¹; Gerardo Velázquez^{1,3} Christopher Aros^{1,8}; Gabriela Navarrete^{1,8};
- 2 Franz Villarroel-Espindola², Maritza Navarrete³, Alberto Fica⁴, Anita Plaza⁵, Natalia Castro5,
- 3 Claudio Verdugo^{5,6}, Gerardo Acosta-Jamett^{5,7} and Cristóbal Verdugo^{5,7}*
- 4
- ⁵ ¹Instituto de Ciencia Animal, Facultad de Ciencias Veterinarias, Universidad Austral de
- 6 Chile, Valdivia, Chile.
- 7 ²Laboratorio Medicina Traslacional, Instituto Oncológico Fundación Arturo López Pérez,
- 8 Santiago, Chile.
- 9 ³Laboratorio de Biología Molecular, Hospital Base de Valdivia (HBV), Valdivia, Chile.
- 10 ⁴SubDepartamento de Medicina, Hospital Base Valdivia; Instituto Medicina, Facultad de
- 11 Medicina, Universidad Austral de Chile, Valdivia, Chile
- 12 ⁵Center for the Surveillance and Evolution of Infectious Diseases (CSEID), Universidad
- 13 Austral de Chile, Valdivia, Chile
- ⁶Instituto de Patología Animal, Facultad de Ciencias Veterinarias, Universidad Austral de
- 15 Chile, Valdivia, Chile.
- ⁷Instituto de Medicina Preventiva, Facultad de Ciencias Veterinarias, Universidad Austral de
- 17 Chile, Valdivia, Chile.
- ⁸Escuela de Bioquímica, Facultad de Ciencias, Universidad Austral de Chile, Valdivia Chile.
- 19
- 20 *Correspondence:
- 21 Dr. Cristobal Verdugo
- 22 <u>cristobal.verdugo@uach.cl</u> NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23

24 Grant ANID COVID N°0585.

25 Key words: SARS-CoV-2, COVID19, Immunoglobulins, Np and RBD, ELISA

26

27 ABSTRACT

The main objective of this study was to estimate the performance, under local 28 29 epidemiological conditions, of two in-house ELISA assays for the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulins. A total of 94 serum samples were 30 31 used for the assessment, where 44 corresponded to sera collected before the pandemic (free SARS-CoV-2 antibodies), and 50 sera were collected from confirmed COVID-19 patients 32 admitted to the main public hospital in the city of Valdivia, southern Chile. The Np and RBD 33 34 proteins were separately used as antigens (Np and RBD ELISA, respectively) to assess their diagnostic performance. A receiver operating characteristic (ROC) analysis was performed to 35 estimate the optical density (OD) cut-off that maximized the sensitivity (Se) and specificity 36 37 (Sp) of the ELISA assays. Np ELISA had a mean Se of 94% (95% CI = 83.5 - 98.8%) and a mean Sp of 100% (95% CI = 92.0 - 100%), with an OD 450 nm positive cut-off value of 38 0.88. On the other hand, RBD ELISA presented a mean Se of 96% (95% CI = 86.3 - 99.5%) 39 and a mean Sp of 90% (95% CI = 78.3 - 97.5%), with an OD 450 nm positive cut off value 40 41 of 0.996. Non-significant differences were observed between the Se distributions of Np and 42 RBD ELISAs, but the latter presented a significant lower Sp than Np ELISA. In parallel, collected sera were also analyzed using a commercial lateral flow chromatographic 43 immunoassay (LFCI), to compare the performance of the in-house ELISA assays against a 44 commercial test. The LFCI had a mean sensitivity of 94% (95% CI = 87.4 - 100%) and a 45 mean specificity of 100% (95% CI = 100 - 100%). When compared to Np ELISA, non-46 significant differences were observed on the performance distributions. Conversely, RBD 47

ELISA had a significant lower Sp than the LFCI. Although, Np ELISA presented a similar
performance than the commercial test, this was 2.5 times cheaper than the LFCI assay. Thus,
the in-house Np ELISA could be a suitable alternative tool, in resource limited environments,
for the surveillance of SARS-CoV-2 infection, supporting further epidemiological studies.

53 INTRODUCTION

54 The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, has caused a global pandemic, which 2.5 years after the first 55 56 reported case (December 2019) has been linked to more than 5 million deaths and more than two hundred million cumulative cases [1]. Since its emergence, several serological assays 57 have been developed to detect the presence of specific antibodies against SARS-CoV-2 [2]. 58 Although, serological approaches cannot distinguish between acute and chronic infection, 59 60 these types of tests are useful for *i*) the identification of individuals who have developed an immune response, *ii*) aid in contact tracing, *iii*) monitoring infection dynamic in the general 61 62 population, and iv) the development of clinical trials [3,4]. The immunoglobulin time response is between 4 to 10-14 days after the onset of symptoms, 63 which limits its applicability for the diagnosis during the acute phase [5,6]. However, the IgM 64 and IgA anti SARS-CoV-2 antibodies develop rapidly in response to the infection, and their 65 detection can significantly increase the diagnostic sensitivity of SARS-CoV-2 infection, 66 67 when serological tests are combined with molecular tests [7]. In particular, IgA antibodies play an important role in mucosal immunity, where IgA may be a better marker of early 68 infection than IgM [8–10]. However, most COVID-19 serological tests are based on the 69 70 detection of IgM and/or IgG antibodies [11]. The preference of IgG and/or IgM detection over IgA, probably is related to a lower specificity of this immunoglobin despite an earlier 71

onset in comparison with IgG and IgM [9]. Nevertheless, the use of assays detecting IgA,

along with IgG and IgM, may be useful in scenarios where it is necessary to maximize the 73 diagnostic sensitivity of the test, such as a screening tool for a surveillance program, for 74 example. Additionally, IgA assays may also be helpful in patients with atypical symptoms, in 75 asymptomatic cases, or when RT-qPCR results remains negative in suspected subjects 76 [12,13]. 77 The detection of circulating antibodies against SARS-CoV-2, as part of a surveillance 78 79 program, requires the use of tools with known sensitivity and specificity [14]. Those parameters would allow to estimate key epidemiological variables, such as the true 80 81 prevalence (TP), when the assay is used in randomized studies. Moreover, accurate TP estimates could be used to assess the performance of passive surveillance systems that most 82 countries have implemented as part of their COVID-19 control strategies [15,16]. 83 84 The main serologic assays used for SARS-CoV-2 detection include the lateral flow 85 chromatographic immunoassay (LFCI) and ELISA tests. In these kinds of assays, the most used viral proteins as antigens are the nucleocapsid protein (Np), which plays a role in the 86 87 transcription and replication of the virus [17,18] and the subunits S1 and S2 of the spike (S) protein [19]. Specifically, S1, containing the receptor binding domain (RBD) for the host 88 angiotensin-converting enzyme (ACE2) receptor; and the S2, containing elements needed for 89 membrane fusion [20,21]. Previous evidence has suggested that the IgG antibodies aiming for 90 91 the S protein are more specific than the anti-Np protein [22,23]. On the other hand, the IgG 92 aiming Np may be more sensitive than those anti-S proteins, particularly in the early phase of 93 infection [22,23]. This could be explained by the relatively high homology in aminoacidic sequence of the SARS-CoV-2 protein Np with the nucleocapsid proteins of other 94 95 Coronaviridae and other viruses [22,24]. Thus, the increased sensitivity of the anti-Np antibody response detection could be at the expense of specificity. The latter may be due to 96 the potential cross-reaction of serological tests to other similar viruses circulating in the target 97

98 population, increasing the false positive rate. In consequence, the performance of any

- 99 serological assay, such as ELISA tests must be optimized and validated under local
- 100 conditions, accounting for endemically circulating viruses.
- 101 The objective of this study was to evaluate and validate two in-house ELISA assays for the
- 102 combined detection of SARS-CoV-2 IgG, IgM and IgA antibodies. To be used for the
- surveillance of COVID-19 in the general population, and to support further epidemiological
- 104 studies. In particular, diagnostic performance indices, such as sensitivity (Se) and specificity
- 105 (Sp), were estimated using sera from pre-pandemic individuals and confirmed COVID-19
- 106 patients
- 107

108 MATERIAL AND METHODS

109 Study population, sample collection and ethics approvals

110 The present study was developed following the Standards for the Reporting of Diagnostic

111 Accuracy Studies (STARD) guidelines proposed by Cohen et al. [25]. A total of 94

individuals were enrolled, where 50 corresponded to confirmed cases of SARS-CoV-2

infection (24 women and 26 men), and 44 corresponded to sera collected between June and

114 July 2019, thus regarded as free of SARS-CoV-2 antibodies sera (pre-pandemic samples). All

115 50 confirmed cases corresponded to unvaccinated patients admitted to the Hospital Base de

116 Valdivia (HBV), Valdivia, southern Chile, from April to November 2020, and they were

117 confirmed by a standard RT-qPCR assay using nasopharyngeal swab samples, as previously

described [26]. At the time of sera collection at the HBV, all were symptomatic cases,

119 presenting different degrees of COVID-19 complications, from very mild to severe, which

- eventually required hospitalization at the HBV. In this line, confirmed cases presented a
- median of 4 days (interquartile range (IQR): 2 6 days) between symptoms onset and RT-
- 122 qPCR diagnosis, whereas serum samples were collected with a median of 11.5 days (IQR: 9 –

15 days) after symptoms onset. This group presented a median age of 58 years (1st Q: 52.5 123 years and 3rd Q: 68.5 years). On the other hand, samples from non-COVID-19 individuals 124 were obtained from a serum bank of an epidemiological study on cystic echinococcosis, 125 where sera were collected from the general population in the Coquimbo region, Chile. This 126 group was composed of 27 women and 17 men, with a median age of 53.5 years (1st Q: 41.5 127 years and 3rd Q: 63.5 years), and 7 out of 44 control-participants presented some type of 128 129 chronic disease, mainly diabetes. Serum samples from non-COVID-19 individuals were obtained and handled following the 130 131 protocol accepted by the Scientific Ethics Committee of the Faculty of Medicine at the Universidad Católica del Norte, Coquimbo-Chile, approved under the resolution 132 CECFAMED-UCN N ° 81/2019. In short, 5 cc of blood was obtained by peripheral 133 venipuncture from volunteers who attended an ultrasound survey for detecting cystic 134 echinococcosis in urban and rural areas in northern Chile. Blood samples were then 135 centrifuged on the same day using a portable centrifuge (Mobilspine, Vulcon Technologies, 136 Richmond, USA), serum was separated and kept in liquid nitrogen in the field and then 137 transferred to a -80°C freezer until further analysis. The samples from the confirmed COVID-138 19 patients were collected following the sample collection protocol of the HBV, where 6 cc 139 of blood were obtained by peripheral venipuncture using yellow or red cap tubes and 140 processed before 4 hours. The use of stored sera, for COVID-19 research purposes, was 141 142 authorized by the Scientific Ethics Committee of the Servicio de Salud Valdivia (SSV), Ministry of Health of Chile, under the resolution SSV Ord.N°187/2020. 143 144 Study design and laboratory analyzes 145

146 The in-house ELISA aims for the combined detection of specific anti-SARS-CoV-2 isotype

147 antibodies (IgA, IgM, and IgG) for the surveillance of COVID-19. To assess the performance

of this assay, sera from pre-pandemic and confirmed cases were assessed by the in-house 148 ELISA test using Np and RBD proteins separately as antigens (Np ELISA and RBD ELISA, 149 respectively), in order to evaluate the performance of each protein. Additionally, analyzes 150 were run in in duplicate and reported optical density (OD) corresponded to the mean between 151 runs. As a quality assurance element, the coefficient of variation between runs was estimated. 152 153 154 In-house ELISAs for combined detection of specific SARS-CoV-2 antibodies Proteins: Recombinant SARS-CoV-2 Np protein (Met1-Ala419, with a C-terminal 6-His tag) 155 156 from Spodoptera frugiperda (R&D System, Catalog Number 10474.CV) (accession #

157 YP 009724397.2). Recombinant SARS-CoV-2 S1 subunit protein (Arg319-Phe541, with a

158 C-terminal 6-His tag) of Host Cell Receptor Binding Domain (RBD) from HEK293 cells

159 (Raybiotech, Catalog Number: 230-30162) (accession # QHD43416.1); Coating step: A final

volume of 50 µl of 20 ng Np or RBD proteins [27] were seeded in a 96-well plate in

161 carbonate buffer pH 9.6 per well and incubated overnight at 4°C. <u>Washing step</u>: After the

incubation time, 3 washes of 5 minutes were carried out with PBS 1x-Tween20 0.05%.

163 <u>Blocking step</u>: the wells were blocked with 200 μ l of blocking solution (1x PBS, 5% BSA,

164 0.05% Tween20) for 2 hours at 37° C, and the content of the plate was discarded, and the

165 washing phase was carried out as previously described. Loading of serum samples: A final

volume of 50 microliters of sample (1:40 dilution in PBS buffer 0.1% w/v of BSA; 0.05% v/v

167 Tween20) [27,28] was loaded and incubated for 2 hours at 37° C. <u>Washing step</u>: After the

incubation time, 3 washes of 5 minutes were carried out with PBS 1x-Tween20 0.05%.

169 <u>Antibodies hybridization step</u>: 100 µl per well of Anti-Human IgA/IgG/IgM (H&L) goat

polyclonal antibody (HRP) (Rockland, R.609-103-130) at a dilution of 1: 10,000 in PBS

buffer 0.1% BSA-0.05% Tween20, were added and incubated for 1 hour at 37° C, the content

172 of the plate was discarded, and the washing phase was carried out as previously described.

173 Finally, the washed wells were developed with TMB reaction and read at 450 nm using a

174 microplate reader HR801 (Shenzhen Highcreation Technology Co. Ltd).

175

176 Performance comparison between the in-house ELISAs and a commercial test

177 To compare the performance of the in-house assays (Np & RBD ELISAs) against a

178 commercially available test. The collected sera were additionally tested using a LFCI kit (The

179 Diagnostic Kit for IgM / IgG Antibody to Coronavirus (SARS-CoV-2) (Lateral Flow),

180 LIVZON, China). This LFCI test was widely used by the Chilean Health Services in the early

stages of the pandemic, and it can separately detect IgG and IgM immunoglobulin isotypes,

using Np as antigen. For this assessment, the LFCI interpretation criteria considered that any

serum showing a signal for IgG or IgM was positive to SARS-CoV-2 infection. Statistical

184 comparison between the LFCI and in-house assays are described below. To complement the

185 comparison between the in-house ELISAs and the commercial LFCI test performance, a cost

186 per sample analyzed at laboratory level was included. The latter evaluation only considered

the cost of the reagents (in-house ELISAs) or the commercial value of the kit (LFCI).

188

189 Statistical analysis

Collected data were analyzed using GraphPad Prism 6 statistical software (USA) and the R 190 software v4.0.2 [29]. They included mean values and standard deviation (mean \pm SD) of the 191 192 optical density (OD) distribution. Those values were subjected to a background subtraction step before data analysis. For comparative analysis of the infected and pre-pandemic OD 193 distributions, a Mann-Whitney U-test was used. A receiver operating characteristic (ROC) 194 195 analysis was conducted to determine the best OD cut-off for the in-house ELISA tests, where sample size was calculated using the equation proposed by Obuchowski, N [30], estimating a 196 minimum of 43 infected and 43 uninfected to yield a study power of 80%, a significance 197

level of 5%, and an expected area under the curve (AUC) of 65%. The ROC and AUC values, 198 in addition to the sensitivity and specificity values, for Np or RBD antigens, were calculated 199 by comparing infected (sera from confirmed COVID-19 patients) and non-infected specimens 200 (sera from pre-pandemic individuals), based on a logistic regression model. The agreement 201 between Np ELISA and RBD ELISA results were assessed using the Cohen' kappa index and 202 the paired McNemar's test. Statistical differences in sensitivity and specificity distributions 203 204 between Np and RBD ELISAs were evaluated using the Kolmogorov-Smirnov test. The overlap area between Np and RBD sensitivity and specificity curves was estimated using the 205 206 "overlapping" package [31] for the R software. Finally, in-house ELISAs and LFCI results were cross tabulated in two-by-two tables and the agreement between them was also 207 evaluated using Cohen' kappa index and the paired McNemar's test, in addition to the 208 209 Kolmogorov-Smirnov test to assess statistical differences between the performance distributions of both tests, where Np ELISA and RBD ELISA were separately compared 210 against the commercial LFCI test. 211

212

213 **RESULTS**

214 In-house ELISAs for specific SARS-CoV-2 antibodies using Np or RBD antigens

215 The Figure 1 shows a representative scheme of used proteins and their location in the SARS-

216 CoV-2 virus, together with the OD distributions of the Np ELISA (left) and RBD ELISA

217 (right) for confirmed cases and controls. At the comparison between duplicated runs, both

assays showed an adequate consistency, and a low error level, with intra-assay variation of

11.2% and 13.4% for Np and RBD ELISAs, respectively. In this way, antibodies against Np

- protein showed that sera from COVID-19 patients had a significantly higher (97%)
- absorbance than sera from pre-pandemic individuals $(1.02 \pm 0.12 \text{ vs } 0.51 \pm 0.13 \text{ OD})$,
- respectively) (P < 0.0001). On the other hand, although to a lesser extent, the immunoassay

against the RBD protein also showed that sera from patients with COVID-19 presented a significantly higher absorbance (43.5%) than sera from pre-pandemic individuals (1.09 +/-0.03 vs 0.71 +/- 0.18 OD, respectively) (P < 0.0001). Interestingly, sera from confirmed COVID-19 patients showed a more homogeneous distributions in their absorbances with the RBD immunoassay than with Np (Figure 1, right and left, respectively). Furthermore, these distributions suggest that most of the analyzed sera presented antibodies that recognize and

bound to both proteins (Np and RBD), and only 2 patients presented antibodies just against
the RBD protein.

231

232 In-house ELISAs performance assessment (sensitivity and specificity estimation)

233 The ROC analysis of the Np ELISA indicated a mean sensitivity of 94% (95% CI = 83.5 -

234 98.8%) and a mean specificity of 100% (95% CI = 92.0 - 100%), with AUC of 0.99 (95%

CI: 0.97 - 1.00) and an OD 450 nm positive cut-off value of 0.88 (Figure 2A). On the other

hand, the ROC analysis of the RBD ELISA had a mean sensitivity of 96% (95% CI = 86.3 –

237 99.5%) and a mean specificity of 90% (95% CI = 78.3 - 97.5%), with AUC of 0.96 (95% CI:

238 0.91-1.00) and an OD 450 nm positive cut off value of 0.996 (Figure 3B). Those cut-offs

represent the point in the ROC curves where the sensitivity and specificity were maximizedfor this set of samples.

241 The agreement between Np and RBD ELISAs was assessed as substantial to perfect

(kappa=0.81, 95% CI = 0.69 - 0.93) based on the qualitative scale interpretation proposed by

Landis and Koch [32] of Cohen's kappa values. Additionally, the dichotomous ELISA results

244 (positive/negative) were not statistically different (P = 0.18) between the two antigens.

Although RBD ELISA presented a relatively higher sensitivity than Np ELISA, those

differences were not statistically significant (P = 0.37), with an overlapping area between

both curves of 69.7% (Figure 3A). Conversely, the use of RBD protein as antigen was

associated to a statistically lower (P < 0.01) specificity, with a shared distribution of 10.8% between the Np and RBD proteins (Figure 3B).

250

251 In-house ELISAs and commercial LFCI test comparison

252 The cross-tabulation between the LFCI test results and SARS-CoV-2 infection status are

253 presented in Table 1, whereas the cross-tabulation of the dichotomous ELISA and

commercial test results are shown in Table 2. Based on the infection status (gold standard),

the LFCI test presented a mean sensitivity of 94% (95% CI = 87.4 - 100%) and a mean

specificity of 100% (95% CI = 100 - 100%). The Cohen' kappa index showed a substantial

to perfect (kappa=0.89, 95% CI = 0.80 - 0.98) agreement between the Np ELISA and the

LFCI test, whereas the agreement between RBD ELISA and the LFCI test was categorized as

substantial kappa=0.78, 95% CI = 0.66 - 0.91). Non-significant differences in the sensitivity

260 (P = 0.999) or specificity (P = 0.999) distributions were observed for the comparison between

261 Np ELISA and the LFCI test. Conversely, the comparison between RBD ELISA and the

LFCI test render a significant difference in the specificity distribution (P < 0.01), but non-

differences were observed between them for the sensitivity distributions (P = 0.999). The use

of the LFCI had a cost of \$10.57 USD per serum analyzed, whereas the Np ELISA and RBD

ELISA had costs of \$4.23 USD and \$2.65 USD per serum, respectively. Thus, the in-house

ELISAs were between 2.5 - 4.0 times cheaper than the used commercial test.

267

268 **DISCUSSION**

269 The present research reports the performance estimation of two in-house ELISA assays for

the surveillance of SARS-CoV-2 infection, which showed a comparable performance than a

commercial test but at a fraction of the cost. Thus, they may be alternative tools for

272 conducting large epidemiological studies in resource limited environments, such as

developing countries. However, the in-house ELISAs require more qualified personnel than 273 the commercial kit, in addition to be more time consuming. In the present study, labor was 274 not considered in the cost comparison. Despite the latter, it is important to note that full-time 275 technicians are commonly present at university laboratories, where a more frequent problem, 276 in developing countries, is the lack of resources to buy reagents rather than labor availability. 277 The OD cut-off optimization and performance estimates considered local epidemiological 278 279 conditions; thus, study results represent the expected performance of the assays in the target population. ROC analysis indicated a non-significant higher sensitivity and statistically 280 281 significant lower specificity of immunoglobins targeting RBD in comparison to Np. In opposition, previous studies have shown a higher Np sensitivity than RBD, and higher 282 specificity of RBD than Np [22,23]. Even though these authors argue that this phenomenon 283 occurs in the early phase of infection, with IgG as the main isotype. In this line, Burbelo et al. 284 285 [17] showed in a longitudinal study that antibodies against Np emerged before antibodies against the S protein. In the present study, confirmed COVID-19 cases had manifested 286 clinical signs before serum collection (median = 11.5 days, IOR: 9 - 15 days). Thus, 287 sensitivity and specificity results reflect the performance of Np and RBD antigens at later 288 stages of the infection under local conditions. Moreover, considering that the intended use of 289 the in-house ELISA assays is for surveillance purposes, study outputs could represent the 290 291 expected performance in the general population, for the detection of past infections of SARS-292 CoV-2. A recent meta-analysis study [19], assessing the performance of serological tests for the detection of antibodies against SARS-CoV-2, has shown that ELISA tests (detecting IgG 293 or IgM) present lower sensitivity than the assays evaluated in this study, where on average 294 295 those assays presented a sensitivity of 84.3% (95% CI: 75.6 – 90.9%). On the other hand, that meta-analysis showed a comparable specificity (range 96.6 - 99.7%), at least for Np ELISA. 296 In this sense, the combined capture of three immunoglobulins, and particularly the inclusion 297

of IgA, could contribute to explaining the higher sensitivity observed. Similarly, Ma et al. 298 [28] reported that measuring IgA in addition to IgG or IgM would increase the sensitivity of 299 the assay. In this line, previous reports have indicated that SARS-CoV-2 elicits robust 300 humoral immune responses, including the production of IgM, IgG, and IgA immunoglobulin 301 isotypes [33]. Patients have been shown to achieve seroconversion and produce detectable 302 antibodies within 20 days from the symptom onset, though the kinetics of IgM and IgG 303 304 production was variable [4,34,35]. A serological screening that includes the detection of IgA, IgM and IgG could be more consistent as a strategy to prevent the spread of the virus, given 305 306 the need to maximize the sensitivity [13], when the diagnostic assay is used as a screening test. 307 Based on the results of the Np and RBD in-house ELISAs, the combined detection of three 308

309 immunoglobulin isotypes (IgA, IgM and IgG) could be more sensitive than assays that only 310 detect one or two immunoglobulin isotypes, particularly for screening purposes or in studies to evaluate the exposition levels in the general population to SARS-CoV-2 virus, regardless 311 of stage, severity, and symptoms of COVID-19 disease. However, the increase in sensitivity 312 is offset by the reduction in specificity, which was especially evident when the RBD antigen 313 was used. This could be also appreciated when contrasting OD distributions for both antigens 314 (Figure 2), where the comparison between control sera showed that RBD ELISA tend to have 315 316 higher OD values than Np ELISA in this group, indicating a lower specificity of this antigen. 317

318 CONCLUSIONS

Considering the intended purpose of the in-house ELISA, a relevant element was to obtain accurate sensitivity and specificity estimates, to support further epidemiological studies. In this sense, estimates for Np ELISA presented a variation (in relation to the mean) between 8 - 16%, whereas RBD ELISA presented a variation between 14 – 21%. Thus, relatively

323	precise estimates were obtained. Moreover, at the comparison with the commercial LFCI test,
324	the Np ELISA presented a comparable performance than the LFCI test, while the RBD
325	ELISA presented a significant lower specificity than the LFCI test and the Np ELISA.
326	Therefore, it can be concluded that the Np ELISA is a better assay than RBD ELISA, which
327	presented performance comparable to a commonly used commercial test, but at a quarter of
328	the cost, making it a viable alternative for surveillance studies in developing countries.
329	
330	DECLARATIONS
331	Competing interest: The authors declare that the research was conducted in the absence of
332	any commercial or financial relationships that could be construed as a potential conflict of
333	interest.
334	
335	Author Contributions: CV (Cristobal) and ARR conceived the idea; CV (Cristobal), ARR,
336	AF, MN, FVE, NC, and AP designed sampling collections and experimental procedures. GV,
337	CA, GN performed laboratory analysis. CV (Cristobal), GA, and CV (Claudio) made the
338	statistical analysis. All the authors wrote, discussed, and approved the final version of this
339	manuscript.
340	
341	Funding: This work received financial support from the National Agency for Research and
342	Development (ANID) of the Ministry of Sciences of Chile, grant number: ANID COVID
343	N°0585.
344	
345	Acknowledgements:
346	A special thanks to Dr. Ratto (Animal Science Institute, UACh) for the facilities granted for
347	access and the use of the photo-documentation machine during the COViD-19 pandemic and

348	to the	Graduate School of the Faculty of Veterinary Sciences (UACh) for co-financing the		
349	acquisition of the plate reader (HR801, Shenzhen Highcreation Technology Co.,Ltd). We			
350	also tl	hank the SEREMI Coquimbo region, Servicio de Salud de Coquimbo, Hospital		
351	Regio	onal de Ovalle, and Municipality of Monte Patria for their logistical support, and Vinka		
352	Valen	cia, Paula Rojas, Cristian Brevis and Paxelia Huertas for their invaluable assistance		
353	during	g field work for the pre-pandemic sampling. Pre-pandemic sampling was supported by		
354	EU-L	AC Health (EULAC/FONIS T020067), through the PERITAS (Molecular		
355	epide	miological studies on pathways of transmission and long-lasting capacity building to		
356	prevent cystic echinococcosis infection) project (G.A. EULACH16/T02-0067;			
357	https://www.iss.it/en/web/iss-en/who-cc-peritas).			
358				
359	REFI	ERENCES		
360	1.	WHO. COVID-19 Weekly Epidemiological Update. In: WHO COVID-19 Weekly		
361		Epidemiological Update, Edition 94 [Internet]. 2022 p. 10. Available:		
362		https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-		
363		191-june-2022		
364	2.	Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et		
365		al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med.		
366		2020;26: 1033-1036. doi:10.1038/s41591-020-0913-5		
367	3.	Huynh A, Arnold DM, Smith JW, Moore JC, Zhang A, Chagla Z, et al. Characteristics		
368		of anti-sars-cov-2 antibodies in recovered covid-19 subjects. Viruses. 2021;13.		
369		doi:10.3390/v13040697		
370	4.	Okba NMA, Müller MA, Li W, Wang C, Geurtsvankessel CH, Corman VM, et al.		
371		Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in		
372		Coronavirus Disease Patients. Emerg Infect Dis. 2020;26. doi:10.3201/eid2607.200841		

373	5.	Padoan A, Padoan A,	, Cosma C, Sciacovelli L,	Faggian D, Plebani	M. Analytical
-----	----	---------------------	---------------------------	--------------------	---------------

- performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and
- antibody kinetics. Clinical Chemistry and Laboratory Medicine. 2020.
- doi:10.1515/cclm-2020-0443
- 377 6. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, et al. Antibody Detection and
- 378 Dynamic Characteristics in Patients with Coronavirus Disease 2019. Clin Infect Dis.
- 379 2020;71. doi:10.1093/cid/ciaa461
- 380 7. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al.
- 381 Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in
- 382 COVID-19. Allergy: European Journal of Allergy and Clinical Immunology. 2020.
- 383 doi:10.1111/all.14364
- Wang P. Significance of IgA antibody testing for early detection of SARS-CoV-2. J
 Med Virol. 2020/12/17. 2021;93: 1888–1889. doi:10.1002/jmv.26703
- 386 9. Yu H-Q, Sun B-Q, Fang Z-F, Zhao J-C, Liu X-Y, Li Y-M, et al. Distinct features of
- 387 SARS-CoV-2-specific IgA response in COVID-19 patients. The European respiratory
- 388 journal. 2020. doi:10.1183/13993003.01526-2020
- Infantino M, Manfredi M, Grossi V, Lari B, Fabbri S, Benucci M, et al. Closing the
 serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-
- 2 IgA antibodies. J Med Virol. 2021;93: 1436–1442.
- 392 doi:https://doi.org/10.1002/jmv.26422
- 11. Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, et al.
- Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody
- detection in severe and mild COVID-19 cases using a Luminex bead-based assay. J
- 396 Virol Methods. 2021;288. doi:10.1016/j.jviromet.2020.114025
- 12. Nuccetelli M, Pieri M, Gisone F, Sarubbi S, Ciotti M, Andreoni M, et al. Evaluation of

- a new simultaneous anti-SARS-CoV-2 IgA, IgM and IgG screening automated assay
- based on native inactivated virus. Int Immunopharmacol. 2021;92.
- 400 doi:10.1016/j.intimp.2020.107330
- 401 13. Jääskeläinen AJ, Kekäläinen E, Kallio-Kokko H, Mannonen L, Kortela E, Vapalahti
- 402 O, et al. Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs
- 403 using coronavirus disease (COVID-19) patient samples. Eurosurveillance. 2020;25.
- 404 doi:10.2807/1560-7917.ES.2020.25.18.2000603
- 405 14. Ibrahim NK. Epidemiologic surveillance for controlling Covid-19 pandemic: types,
- 406 challenges and implications. J Infect Public Health. 2020;13: 1630–1638.
- 407 doi:https://doi.org/10.1016/j.jiph.2020.07.019
- 408 15. Goldstein ND, Wheeler DC, Gustafson P, Burstyn I. A Bayesian approach to
- 409 improving spatial estimates of prevalence of COVID-19 after accounting for
- 410 misclassification bias in surveillance data in Philadelphia, PA. Spat Spatiotemporal

411 Epidemiol. 2021;36: 100401. doi:10.1016/j.sste.2021.100401

- 412 16. Burstyn I, Goldstein ND, Gustafson P. Towards reduction in bias in epidemic curves
- 413 due to outcome misclassification through Bayesian analysis of time-series of
- 414 laboratory test results: case study of COVID-19 in Alberta, Canada and Philadelphia,
- 415 USA. BMC Med Res Methodol. 2020;20: 146. doi:10.1186/s12874-020-01037-4
- 416 17. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, et al. Detection of
- 417 Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike
- 418 Protein in COVID-19 Patients. medRxiv Prepr Serv Heal Sci. 2020.
- 419 doi:10.1101/2020.04.20.20071423
- 42018.Tok TT, Tatar G. Structures and Functions of Coronavirus Proteins: Molecular
- 421 Modeling of Viral Nucleoprotein. Int J Virol Infect Dis. 2017;2.
- 422 19. Lisboa-Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui L-P, Johnston JC, et

- 423 al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-
- 424 analysis. BMJ. 2020;370: m2516. doi:10.1136/bmj.m2516
- 425 20. Espejo AP, Akgun Y, Mana AF Al, Tjendra Y, Millan NC, Gomez-Fernandez C, et al.
- 426 Review of current advances in serologic testing for COVID-19. American Journal of
- 427 Clinical Pathology. 2020. doi:10.1093/AJCP/AQAA112
- 428 21. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel
- 429 coronavirus spike protein by a SARS coronavirus-specific human monoclonal
- 430 antibody. Emerging Microbes and Infections. 2020.
- doi:10.1080/22221751.2020.1729069
- 432 22. Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses:
- 433 Challenges and pitfalls. Virus Res. 2014;194. doi:10.1016/j.virusres.2014.03.018
- 434 23. Fenwick C, Turelli P, Pellaton C, Farina A, Campos J, Raclot C, et al. A high-
- 435 throughput cell- And virus-free assay shows reduced neutralization of SARS-CoV-2

436 variants by COVID-19 convalescent plasma. Sci Transl Med. 2021;13.

- doi:10.1126/scitranslmed.abi8452
- 438 24. Infantino M, Damiani A, Gobbi FL, Grossi V, Lari B, Macchia D, et al. Serological
- 439 assays for sars-cov-2 infectious disease: Benefits, limitations and perspectives. Isr Med
 440 Assoc J. 2020;22.
- 441 25. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD
- 442 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration.
- 443 BMJ Open. 2016;6. doi:10.1136/bmjopen-2016-012799
- 444 26. Olivares F, Muñoz D, Fica A, Delama I, Alvarez I, Navarrete M, et al. Covid-19 in
- 445 Chile. The experience of a Regional reference Center. Preliminary report. medRxiv.
- 446 2020; 2020.06.14.20130898. doi:10.1101/2020.06.14.20130898
- 447 27. Woo PCY, Lau SKP, Tsoi H, Chan K, Wong BHL, Che X, et al. Relative rates of non-

- 448 pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet
- 449 (London, England). 2004;363: 841–845. doi:10.1016/S0140-6736(04)15729-2
- 450 28. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG
- 451 responses in COVID-19. Cellular and Molecular Immunology. 2020.
- 452 doi:10.1038/s41423-020-0474-z
- 453 29. R_Core_Team. R: A Language and Environment for Statistical Computing. Vienna,
- 454 Austria: R Foundation for Statistical Computing; 2019.
- 455 30. Obuchowski NA. ROC analysis. AJR Am J Roentgenol. 2005;184: 364–372.
- 456 doi:10.2214/ajr.184.2.01840364
- 457 31. Pastore M. Overlapping: a R package for Estimating Overlapping in Empirical
- 458 Distributions. J Open Source Softw. 2018;32: 1023.
- 459 32. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
 460 Biometrics. 1977;33: 159–174.
- 33. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the
- 462 early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13.
- doi:10.1126/scitranslmed.abd2223
- 464 34. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling early humoral
- response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020;71.
- 466 doi:10.1093/cid/ciaa310
- 467 35. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to
 468 SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26. doi:10.1038/s41591-
- 469 020-0897-1

470

472 FIGURE CAPTIONS

- 473 Figure 1: Combined immunodetection of SARS-CoV-2-specific IgA/IgM/IgG
- immunoglobulins in response against the Nucleocapsid (Np) and Region Binding Domine of
- 475 Spike Protein (RBD). Oil painting picture schematic of SARS-CoV-2 viral structure (top
- 476 panel), N-protein (Np) and RBD from S-protein are showed in red and light orange,
- 477 respectively. Absorbance at 450 nm plotted for combined detection of IgA, IgM, and IgG
- 478 specific immunoglobulin isotypes for Np and RBD ELISAs (lower left and lower right panel,
- respectively). Forty-four sera from pre-pandemic individuals and fifty sera from COVID-19
- 480 patients were tested. To compare both groups, a Mann-Whitney U-test was used. Mean+/-SD
- 481 and P values are showed (P < 0.0001).

482

- 483 Figure 2: Receiver Operating Characteristic (ROC) curves for the combined detection of
- 484 SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes using RBD or Np antigens.
- 485 Graph of ROC curve and two graph curves (sensitivity and specificity for different cut-off)
- 486 for Np-specific immunoglobulins (Panel A: top and bottom, respectively), and RBD-specific
- 487 immunoglobulins (Panel B: top and bottom, respectively), are shown. Forty-four sera from
- pre-pandemic individuals and fifty sera from COVID-19 patients were tested. AUC, areaunder the curve of ROC.
- 490

Figure 3: Estimated sensitivity and specificity distribution curves for the selected OD cut off
(Np = 0.88 & RBD = 0.996). The overlapping area between the sensitivity curves of Np
ELISA vs. RBD ELISA (Panel A), and the overlapping area between the specificity curves of
Np ELISA vs. RBD ELISA (Panel B).

495

496 Table 1. Cross-tabulation of in-house ELISAs (Np & RBD ELISA) results and a commercial

		LFCI*	
		Positive	Negative
Np	Positive	44	2
ELISA	Negative	3	45
		Positive	Negative
RBD	Positive	44	7
ELISA	Negative	3	40

497 lateral flow chromatographic immunoassay (LFCI) result

498 The Diagnostic Kit for IgM / IgG Antibody to Coronavirus (SARS-CoV-2) (Lateral Flow), LIVZON, China

499

501 Table 2. Cross-tabulation of SARS-CoV-2 infection status and a commercial lateral flow

502 chromatographic immunoassay (LFCI) test result

		Disease Status		
		Confirmed	Control	
I ECI*	Positive	47	0	
LFUI	Negative	3	44	

503 The Diagnostic Kit for IgM / IgG Antibody to Coronavirus (SARS-CoV-2) (Lateral Flow), LIVZON, China

504



Figure 1











Figure 2



Figure 3